News

Co-stimulators of drug-trial disaster identified
Enlarge image

BusinessGermany

Co-stimulators of drug-trial disaster identified

14.05.2012 - German researchers found a potential co-factor that triggered the cytokine storm, which led to hospitalisation of six volunteers treated with TGN1412.

Langen – A team of German researchers from the Paul-Ehrlich-Institut (PEI) has identified an important mechanism that can explain how immunotherapy drug TGN1412 might have triggered the catastrophic immune reaction responsible for the 2006 Northwick Park trial. The drug-trial disaster left six healthy volunteers hospitalised. The team, led by Zoe Waibler, reports that TGN1412-mediated T cell proliferation and cytokine release triggered by the superagonistic CD28-specific antibody, requires an interaction of an inducible co-stimulator on T cells (ICOS) with its ligand on endothelial cells (LICOS).  The team reports in the journal Blood. "We found that co-stimulatory ICOS-LICOS interaction between T cells and endothelial cells is critically involved in TGN1412-mediated effects."

The Phase I clinical trial of TGN1412 took place at an independent clinical trials unit at Northwick Park and St Mark's Hospital, London, on 13 March 2006. TGN1412 was intended for the treatment of leukaemia, multiple sclerosis and rheumatoid arthritis. Eight volunteers were given the drug or a placebo by intravenous infusion, with an interval of about 10 minutes between patients. Within minutes of the last patient being administered the drug, the first began to complain of headache, followed by fever and pain. The five other patients to receive TGN1412, as opposed to the placebo, became seriously ill soon afterwards. All six male volunteers experienced cytokine release syndrome (cytokine storms) with effects similar to those of people suffering a severe allergic reaction. Each of the men was hospitalised for several weeks, with the worst affected requiring hospital treatment for four months.  The drug developing company, TeGenero Immuno Therapeutics from Germany, entered into insolvency proceedings later in 2006. It assets were sold to German-Russian Theramab LLC, which develops TGN1412 under the new name TAB08 as therapy for B-cell chronic lymphocytic leukaemia and rheumatoid arthritis.

http://www.european-biotechnology-news.com/news/news/2012-02/co-stimulators-of-drug-trial-disaster-identified.html

EU

04.09.2015 Crowdfinancing has just recently emerged as a financing instrument in the Life Sciences. A new report lists 42 European companies in the sector that have raised a total of almost €23m.

DiabetesFrance

01.09.2015 Sanofi is partnering up with Google’s life sciences team with an ambitious goal: to change the face of diabetes management.

M&ASwitzerlandFrance

31.08.2015 In order to boost its active cosmetic ingredients business, the Swiss flavour and fragrance giant Givaudan has acquired Volketswil-based Induchem Holding and all its subsidiaries.

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • EVOLVA (CH)1.49 CHF12.03%
  • TIGENIX (B)1.23 EUR9.82%
  • OREXO (S)49.10 SEK8.39%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)11.35 SEK-11.67%
  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • PROTHENA PLC (IE)52.70 USD-6.54%

TOP

  • KARO BIO (S)41.90 SEK2424.1%
  • BIOTECH PHARMACON (N)16.80 NOK76.8%
  • TIGENIX (B)1.23 EUR73.2%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • NEUROVIVE PHARMACEUTICAL AB (S)11.35 SEK-48.4%
  • THROMBOGENICS (B)2.85 EUR-43.0%

TOP

  • KARO BIO (S)41.90 SEK4661.4%
  • ADOCIA (F)89.30 EUR434.4%
  • GALAPAGOS (B)53.25 EUR330.1%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • NEUROVIVE PHARMACEUTICAL AB (S)11.35 SEK-82.2%
  • BIOTEST (D)20.30 EUR-76.5%

No liability assumed, Date: 04.09.2015